SINGAPORE, Nov. 3, 2022 /PRNewswire/ — Oncoshot has simply introduced certainly one of its greatest collaborations to date with Icon Cancer Centre in Singapore, alongside Roche. Together the companions plan to facilitate extra complete genomic profiling information to improve entry to extra trial choices for most cancers sufferers. This first-ever collaboration in SEA will assist advance the biopharmaceutical analysis and growth ecosystem for healthcare professionals, establishments and sufferers by taking a extra personalised method to care and providing folks with most cancers extra remedy choices.
Presently, the most cancers genomic testing course of encompasses organic sampling from a affected person, after which the check outcomes are returned to the requesting physician. Unless a health care provider is conscious of an present medical trial, they’re doubtless to prescribe their affected person a regular remedy at that juncture. Through this collaboration, Oncoshot, Icon and Roche will probably be ready to simply determine most cancers sufferers who’re a match for present medical trials being run inside their networks. Furthermore, real-time inhabitants matching will even allow firms and medical analysis organisations (CROs) on the Oncoshot medical trial platform to have interaction Icon as a most popular medical trial centre, rising affected person entry to medical trial choices for his or her most cancers.
“This collaboration marks our commitment to advancing cancer care and increasing access to the latest in cancer clinical trials. By digitising a patient’s genomic profile, we are able to accelerate the process of matching patients to the most suitable clinical trials,” stated Serena Wee, CEO of Icon ASEAN and Hong Kong. “By investing in this partnership, our patients can access new and emerging advances in cancer treatment quicker, giving them and their families new hope and opportunities.”
“With comprehensive genomic profiling (CGP) data, healthcare professionals can make more informed decisions for their patients about potential treatment options, which should include access to clinical trials of investigational new medicines,” stated Ying Ying Yeoh, General Manager for Roche Singapore. “We are proud to partner with Oncoshot and Icon to help more patients in our collective fight against cancer, and advance clinical cancer research in APAC to bring more medicines to patients sooner.”
As a part of this collaboration, Roche will present CGP information from assessments that analyse over 300 genes identified to drive most cancers development.
About Oncoshot
Oncoshot was based in 2018 by Medical Oncologist Dr Huren Sivaraj and Data Science Engineer Ruslan Enikeev. As a well being insights trade platform, Oncoshot leverages its proprietary medical trial-matching synthetic intelligence know-how to deal with the inefficiencies of most cancers medical trials. The platform serves as a bridge between main regional healthcare establishments and CROs and world biotechnology and pharmaceutical firms to facilitate data-driven most cancers medical trials whereas accelerating enrolment into actively recruiting ones.
For extra data, go to www.oncoshot.com.
About Icon Cancer Centre
Icon Cancer Centre is a number one personal most cancers care supplier delivering a holistic method to most cancers care. Icon Cancer Centre is a part of Icon Group, a world most cancers care supplier with over 50 centres globally. Icon Cancer Centre has seven specialist clinics in Singapore and a devoted well being screening clinic. With a outstanding and skilled group of medical oncologists, radiation oncologists, haematologists, paediatric haematologist-oncologists, palliative care specialists, basic practitioners and visiting surgical oncologists, Icon gives end-to-end most cancers care from screening and analysis, via to remedy and past.
For extra data, go to www.iconcancercentre.sg.
